Chapter 4

Pharmacological Prevention of Recurrent Stones

S. Jishnu[a*], Kazi Amin Wasim[a] ,A.Ramya[b*]

[a]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences , Vels Institutes of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: ramya.sps@vistas.ac.in*

Abstract

Recurrent nephrolithiasis is a common and challenging condition; with nearly half of affected individuals develop new stones within ten years. Pharmacological prevention, guided by metabolic evaluation and analysis of stone composition, is central to reducing recurrence risk. Thiazide diuretics are widely used in patients with hypercalciuria, as they lower urinary calcium excretion and thereby reduce calcium stone formation. Potassium citrate is effective in correcting hypocitraturia and alkalinizing urine, which prevents calcium oxalate and uric acid stones. Allopurinol, by inhibiting uric acid synthesis, is beneficial in patients with hyperuricosuria or uric acid stones. Other agents, such as magnesium supplements and acetohydroxamic acid, have limited or specialized roles, particularly in struvite stones. Evidence from randomized controlled trials demonstrates that tailored pharmacological therapy, when combined with lifestyle measures such as adequate hydration, sodium restriction, and moderated protein intake, can reduce recurrence

ISBN 978-816855388-0

rates by 40–60%. Despite proven efficacy, long-term adherence and monitoring for adverse effects are essential to ensure sustained benefit. Thus, individualized pharmacological intervention, integrated with dietary and behavioral strategies, represents the cornerstone of recurrent stone prevention and remains a critical component of comprehensive management in patients at risk of recurrence.

Keywords: Recurrent nephrolithiasis; Kidney stone prevention, Pharmacological therapy; Thiazide diuretics; Hypercalciuria.

1. Introduction

Pharmacological prevention of recurrent stones involves a combination of dietary measures and medications. Thiazide diuretics are commonly used to decrease urinary calcium levels, thereby reducing the recurrence of kidney stones [1,3]. Higher dose of thiazides have been associated with a greater reduction in urinary calcium levels and decreased the kidney recurrent stones [1]. Potassium citrate is another medication that can be used to prevent recurrent stones, especially with recurrent calcium-containing stones. It is recommended for people with recurrent stones with low pH that persists despite nutrition therapy [2,3]. It is essential to consider the patients overall health and the potential side effects of these medications when deciding on the appropriate pharmacological prevention [1].

2. Thiazide diuretics

Thiazide diuretics are can be classified into two categories based on their molecular structure: thiazide-type diuretics and thiazide-like diuretics. Examples of thiazide-type diuretics include hydrochlorothiazide, chlorothiazide, and methyclothiazide. Thiazide-

like diuretics such as indapamide, metolazone, and chlorthalidone [7,8]. Possess different molecular structures but share a similar mechanism of action. A meta-analysis of randomized controlled studies in patients with hypertension demonstrated that thiazide-like diuretics provide a 12% greater reduction in cardiovascular events and a 21% greater reduction in heart failure risk compared to thiazide-type diuretics, with comparable adverse event rates [7] .

2.1 Mechanism of action

Thiazide diuretics exert their diuretic effect via blockage of the sodium-chloride channel in the proximal segment of the distal convoluted tubule [7,8]. When the channel is blocked. Thiazide diuretics inhibit the sodium–chloride co-transporter in the distal convoluted tubule. This inhibition reduces sodium reabsorption, leading to increased sodium and water excretion in the urine. As a result, urinary calcium excretion is reduced, which contributes to the prevention of calcium stone formation. The activation method for thiazide diuretics can causes the changes in sodium concentration distal to the DCT. This secondary change to balance sodium levels can produce many side effects. The blockage of the sodium channel can cause the increases in sodium and water retention in the lumen and it will decrease the in sodium in the DCT. At the same time blockage of the sodium channel can causes to increase the flow of ions through the sodium channel. This increases the sodium level causes the aldosterone-sensitive sodium or sodium pump to increase the sodium re absorption in the cells of the kidney. This loss the K+ transfer into the collecting as tubules[7]. This loss the k+ pump, which is aldosterone mediated. The results in increased reabsorption of sodium and excretion of both K+ and H+ Ions [8].

ISBN 978-816855388-0

2.2 Potassium citrate

The pharmacological prevention of potassium citrate involves the use of potassium citrate to manage the conditions leading to formation of kidney stone [2]. It is used to treat the renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis [2,3]. Potassium citrate works by increasing the urinary citrate level and pH, making the urine less susceptible to the formation of kidney stones. It is particularly effective in preventing calcium phosphate stones and uric acid stones [1,3]. Management of struvite stones should be avoided and they have some infections-related to the kidney [2]. They have some alternative for potassium citrate is sodium bicarbonate or poorly tolerated. The urine sodium will be increases and calcium is essential and the urine can increase the risk of calcium phosphate stones [1]. Studies have shown that potassium citrate therapy may reduce stone recurrence by up to 75% [1].

3. Dosage and Administration

The dosage of Potassium citrate can vary based on the condition being treated:

Adults: The dosages range from 10 to 30 mEq it will be taken orally and it is divided into two or three doses per day. For better absorption it is administered with meals [7].

Pediatrics: For children, the dosage is can be calculated is based on the body weight, typically around 1 to 2 m Eq/kg/day, it will be divides into multiple doses [8].

3.1 Allopurinol Therapy

Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication [7].

Allopurinol is FDA approved for the following indications:

1. Gout
2. Prevention of tumor lysis syndrome
3. Prevention of recurrent calcium nephrolithiasis in patients with hyperuricosuria [3,7]

Other non-FDA-approved indications include Lesch-Nyhan syndrome-associated hyperuricemia and recurrent uric acid nephrolithiasis prevention [7].

It is important to note that asymptomatic hyperuricemia is not an indication of allopurinol therapy [7] .

3.2 Mechanism of action

Allopurinol undergoes metabolism in the liver, where it transforms into its pharmacologically active metabolite, oxypurinol [7]. The half-life of allopurinol is 1 to 2 hours, and oxypurinol is about 15 hours [7]. Both allopurinol and oxypurinol are renally excreted. Allopurinol and oxypurinol both inhibit xanthine oxidase, an enzyme in the purine catabolism pathway that converts hypoxanthine to xanthine to uric acid [7,8].

Prieto-Moure B. et al. conducted research on small intestine ischemia-reperfusion injury of Wistar rats and the role of allopurinol and dantrolene in preventing oxygen-free radical damage. The researchers found that the allopurinol and dantrolene combination provided antioxidant effects, which decreased the oxygen-free radical damage caused by the ischemia-reperfusion in the rat's small intestines.

4. *Conclusion*

ISBN 978-816855388-0

Pharmacological therapy remains a cornerstone in the prevention of recurrent nephrolithiasis, particularly in patients with identifiable metabolic abnormalities [1,3]. Thiazide diuretics, potassium citrate, and allopurinol are the most effective and evidence-based agents, each targeting specific risk factors such as hypercalciuria, hypocitraturia, and hyperuricosuria [1,2,3]. While other agents like magnesium supplements and acetohydroxamic acid have limited or specialized applications, their role underscores the importance of individualized treatment. Clinical evidence consistently demonstrates that pharmacological intervention, when combined with lifestyle measures such as adequate hydration, sodium restriction, and moderated protein intake, can reduce recurrence rates by up to 60% [1]. Long-term success depends not only on the appropriate selection of therapy but also on patient adherence and careful monitoring for adverse effects. Ultimately, a tailored, multifaceted approach that integrates pharmacological treatment with dietary and behavioral strategies offers the most effective means of reducing stone recurrence and improving patient outcomes [2,3].

References

[1] Fink, H. A., Wilt, T. J., Eidman, K. E., Garimella, P. S., MacDonald, R., Rutks, I. R., Brasure, M., Kane, R. L., Ouellette, J., & Monga, M. (2013). Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. *Annals of internal medicine*, *158*(7), 535–543. https://doi.org/10.7326/0003-4819-158-7-201304020-00005

[2] Türk, C., Petřík, A., Sarica, K., Seitz, C., Skolarikos, A., Straub, M., & Knoll, T. (2016). EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. *European urology*, *69*(3), 468–474. https://doi.org/10.1016/j.eururo.2015.07.040.

[3] Pearle, M. S., Goldfarb, D. S., Assimos, D. G., Curhan, G., Denu-Ciocca, C. J., Matlaga, B. R., Monga, M., Penniston, K. L., Preminger,

G. M., Turk, T. M., White, J. R., & American Urological Association (2014). Medical management of kidney stones: AUA guideline. *The Journal of urology*, *192*(2), 316–324. https://doi.org/10.1016/j.juro.2014.05.006.

[4] Pak, C. Y., Peterson, R., Sakhaee, K., Fuller, C., Preminger, G., & Reisch, J. (1985). Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. *The American journal of medicine*, *79*(3), 284–288. https://doi.org/10.1016/0002-9343(85)90305-5.

[5] Maschio G, Tessitore N, D'Angelo A, Fabris A, Pagano F, Tasca A, et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. *Am J Med.* 1981;71(4):623-626.

[6] Brunton LL, Hilal-Dandan R, Knollmann BC. *Goodman & Gilman's The Pharmacological Basis of Therapeutics.* 13th ed. New York: McGraw-Hill; 2018.

ISBN 978-816855388-0